why choose us

First received: January 6, 2023

Clinical Trial: Early Access Program for ALXN1840 in Patients With Wilson Disease

Study Type: Expanded Access


Brief Summary: This is an open-label, single-arm, multi-center EAP, designed to provide early access to ALXN1840 for eligible patients with WD.

Read more